CHEO Research Institute Logo
Decrease Text SizeIncrease Text SizeFacebookTwitterYoutube

researchers working in a lab

David Stojdl, PhD photo of Dr David Stojdl
Senior Scientist, Apoptosis Research Centre, CHEO Research Institute
Associate Professor, Department of Pediatrics, University of Ottawa
Research Practice Areas:
Current Research:
Visit Dr. Stojdl's lab website

The Stojdl lab is interested in using biology to fight biology. Our approach has been directed at developing programmable replicating viruses called “oncolytic viruses” to directly target and kill tumour cells as well as manipulate the tumour microenvironment to further kill primary and metastatic cancer cells. In recent years we have discovered a new oncolytic virus called Maraba virus that is potent at treating both adult and paediatric solid tumour in preclinical models. We are now working together with collaborators at the Ottawa Hospital Research Institute and McMaster University with funding through the Ontario Institute for Cancer Research to initiate a phase I clinical trial of our Maraba oncolytic platform. For more information about our research, go to:
Research Team:
Sample Publications:

Allan KJ, Stojdl DF, Swift SL. High-throughput screening to enhance oncolytic virus immunotherapy. Oncolytic Virother 2016; 5:15-25.

Courteau L, Crasto J, Hassanzadeh G, Baird SD, Hodgins J, Liwak-Muir U, Fung G, Luo H, Stojdl DF, Screaton RA, Holcik M. Hexokinase 2 controls cellular stress response through localization of an RNA-binding protein. Cell Death Dis 2015; 6: e1837.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben ND, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC. Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med 2015; 21 (5): 530-6.

Roy DG, Power AT, Bourgeois-Daigneault MC, Falls T, Ferreira L, Stern A, Tanese de Souza C, McCart JA, Stojdl DF, et al. Programmable insect cell carriers for systemic delivery of integrated cancer biotherapy. J Control Release 2015; 220 (Pt A): 210-21.

Tong JG, Valdes YR, Barrett JW, Bell JC, Stojdl D, McFadden G, et al. Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. Molecular Therapy-Oncolytics 2015; 2.

Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer 2014; 14(8):559-567.

Mahoney DJ, Stojdl DF, Laird G. Virus therapy for cancer. Sci Am 2014; 311(5):54-59.

Muik A, Stubbert LJ, Jahedi RZ, Geibeta Y, Kimpel J, Dold C, Tober R, Volk A, Klein S, Dietrich U, Yadollahi B, Falls T, Miletic H, Stojdl D, Bell JC, von LD. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency. Cancer Res 2014; 74(13):3567-3578.

Pol JG, Zhang L, Bridle BW, Stephenson KB, Resseguier J, Hanson S, Chen L, Kazdhan N, Bramson JL, Stojdl DF, Wan Y, Lichty BD. Maraba virus as a potent oncolytic vaccine vector. Mol Ther 2014; 22(2):420-429.

Tesfay MZ, Ammayappan A, Federspiel MJ, Barber GN, Stojdl D, Peng KW, Russell SJ. Vesiculovirus neutralization by natural IgM and complement. J Virol 2014; 88(11):6148-6157.

Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, Wang J, Sahi S, Ly L, Lefebvre C, Falls TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol Ther 2014; 22(7):1320-1332.

Take Action
Quick Links

Our Researchmagnifying glass

abcefg hijklmnopqrst uvwxyz